Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)

[PR Newswire] – NORTH CHICAGO, Ill., June 2, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including … Read more on this. AbbVie Inc. (ABBV) , currently valued at $104.21B, started trading this morning at $62.87. Today’s price range has been between $62.83 and $64.66 per share and has traded between $45.45 and $71.60 over the past year. AbbVie (ABBV) shares are currently priced at 13.20x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.14x earnings multiple for the same period. And for passive income investors, the company pays shareholders $2.28 per share annually in dividends, yielding 3.62%. According to a consensus of 17 analysts, the earnings estimate of $1.20 per share would be $0.12 better than the year-ago quarter and a $0.04 sequential decrease. The full-year EPS estimate is $4.76 which would be a $0.47 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $6.20 Billion. If reported, that would be a 13.14% increase over the year-ago quarter. In terms of ratings, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. The average price target for ABBV shares by the analysts covering the stock is $71.06, which is 13.03% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Progress in Oncology Research at ASCO 2016 Annual Meeting with Multiple Abstracts Evaluating Eight Medicines Across Cancer Types Company Update: AbbVie Inc (NYSE:ABBV) – Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at the Bank of America Merrill Lynch 2016 Global Health Care Conference